QNRX QUOIN PHARMACEUTICALS LTD US FDA Inspections 8-K Filing 2025 - Clinical Trials On May 22, 2025, Quoin Pharmaceuticals announced that it received FDA clearance to start a second pivotal clinical study for its lead product, QRX003, targeting Netherton Syndrome.Get access to all SEC 8-K filings of the QUOIN PHARMACEUTICALS LTD